Concurrent <i>TP53</i> and <i>CDKN2A</i> Gene Aberrations in Newly Diagnosed Mantle Cell Lymphoma Correlate with Chemoresistance and Call for Innovative Upfront Therapy

Concurrent <i>TP53</i> and <i>CDKN2A</i> Gene Aberrations in Newly Diagnosed Mantle Cell Lymphoma Correlate with Chemoresistance and Call for Innovative Upfront Therapy

Mantle cell lymphoma (MCL) is a subtype of B-cell lymphoma with a large number of recurrent cytogenetic/molecular aberrations. Approximately 5–10% of patients do not respond to frontline immunochemotherapy. Despite many useful prognostic indexes, a reliable marker of chemoresistance is not available...

Full description

Bibliographic Details
Main Authors: Diana Malarikova, Adela Berkova, Ales Obr, Petra Blahovcova, Michael Svaton, Kristina Forsterova, Eva Kriegova, Eva Prihodova, Lenka Pavlistova, Anna Petrackova, Zuzana Zemanova, Marek Trneny, Pavel Klener
Format: Article
Language:English
Published: MDPI AG 2020-07-01
Series:Cancers
Subjects:
mantle cell lymphoma
TP53
CDKN2A
prognostic markers
chemoresistance
Online Access:https://www.mdpi.com/2072-6694/12/8/2120

Internet

https://www.mdpi.com/2072-6694/12/8/2120

Similar Items